Advertisement

Topics

Latest "Aimmune Therapeutics" News Stories

04:37 EST 11th December 2018 | BioPortfolio

Here are the most relevant search results for "Aimmune Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Aimmune Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Aimmune Therapeutics for you to read. Along with our medical data and news we also list Aimmune Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Aimmune Therapeutics Companies for you to search.

Showing "Aimmune Therapeutics" News Articles 1–25 of 8,100+

Extremely Relevant

Nestle Health increases stake in Aimmune Therapeutics

Nestlé Health Science has raised its equity stake in biopharmaceutical firm Aimmune Therapeutics to around 19% with an investment of...Read More... The post Nestle Health increases stake in Aimmune Therapeutics appeared first on Pharmaceutical Technology.


Jayson Dallas Leaves Ultragenyx for CEO Post at Aimmune

Jayson Dallas has been appointed CEO of food allergy therapy developer Aimmune Therapeutics. Before joining Brisbane, CA-based Aimmune, Dallas was the chief commercial officer of Ultragenyx (NASDAQ: RARE) in Novato, CA. Dallas succeeds Stephen Dilly, who last year announced his plans to retire from Aimmune. The company says Dilly will continue to serve as an […]

Aimmune Therapeutics begins Phase II trial of AR101 and dupilumab

Aimmune Therapeutics has started a Phase II trial of AR101 with adjunctive dupilumab for the treatment of patients with peanut...Read More... The post Aimmune Therapeutics begins Phase II trial of AR101 and dupilumab appeared first on Drug Development Technology.


Nestlé Health Science increases stake in Aimmune Therapeutics

Aimmune Therapeutics is engaged in the development of advanced treatments for life-threatening food allergies. The latest investment brings Nestlé’s total investment in the drug developer for food allergies The post Nestlé Health Science increases stake in Aimmune Therapeutics appeared first on Pharma Business review.

Aimmune Therapeutics Announces Initiation of Phase 2 Study With Regeneron and Sanofi of AR101

Aimmune Therapeutics (Nasdaq:AIMT) a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the initiation of a phase 2 study, with Regeneron and Sanofi, of AR101 with adjunctive dupilumab in peanut-allergic patients. As quoted in the press release: AR101 is Aimmune’s investigational biologic oral immunotherapy for desensitization of pat...

Nestle erhöht Beteiligung an US-Biopharmaspezialisten Aimmune

Von Colin Kellaher LONDON (Dow Jones)--Nestle erhöht seine Beteiligung an dem US-Biopharmaunternehmen Aimmune Therapeutics. Der Schweizer Konzern investiert weitere 98 Millionen US-Dollar und erhö...

Relevant

Aimmune expects FDA decision on peanut allergy therapy in August 2019

Aimmune Therapeutics anticipates an FDA advisory committee meeting for the approval of its lead oral immunotherapy candidate AR101 evaluated to treat peanut allergies,...Read More... The post Aimmune expects FDA decision on peanut allergy therapy in August 2019 appeared first on Pharmaceutical Technology.

Nestle raises stake in food allergy drug developer Aimmune

The health science unit of Nestle SA would pay $98 million to increase its stake in Aimmune Therapeutics Inc, the drug developer for food allergies said on Monday.

Aimmune Therapeutics to Present at the Cantor Global Healthcare Conference on Wednesday, October 3

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that President and CEO Jayson Dallas, M.D., will participate in a fireside chat at the Cantor Global Healthcare Conference in New York on Wednesday, October 3, 2018, at 10:55 a.m. Eastern Time. A live we...

Aimmune Therapeutics Announces Closing of $98 Million Investment by Nestlé Health Science

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the closing of the $98 million equity investment by Nestlé Health Science. Nestlé Health Science purchased 3,237,529 newly issued shares of Aimmune’s common stock at $30.27 per share on November 28...

Aimmune Therapeutics On Track For Major Breakthrough

Aimmune Therapeutics: Special Situation Biotech Opportunity

Aimmune publishes phase III data for peanut allergy drug

Aimmune has published the data from its phase III PALISADE clinical trial into AR101, a biologic immunotherapy indicated for desensitisation...Read More... The post Aimmune publishes phase III data for peanut allergy drug appeared first on Pharmaceutical Technology.

Aimmune Therapeutics (AIMT) Presents At 38th Nasdaq Investor Conference - Slideshow

Aimmune Therapeutics: An Interesting Business and Charts to Watch

Click to view a price quote on AIMT.

Aimmune Therapeutics to Participate in Upcoming Investor Conferences

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of senior management will participate in the following investor conferences: Stifel 2018 Healthcare Conference (November 13, New York): Fireside chat with Eric Bjerkholt, CFO, sta...

Aimmune Therapeutics to Present at Three Investor Conferences in September

Wells Fargo Healthcare Conference, September 5 Baird Global Healthcare Conference, September 6 Bank of America Merrill Lynch Global Healthcare Conference, September 12 Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today ...

Aimmune Therapeutics to file peanut allergy treatment AR101 with FDA next month, EU regulators in mid-2019 https://www.firstwordpharma.com/node/1605338?tsid=28®ion_id=6 …

Aimmune Therapeutics to file peanut allergy treatment AR101 with FDA next month, EU regulators in mid-2019 https://www.firstwordpharma.com/node/1605338?tsid=28&region_id=6 …

Aimmune Therapeutics Announces CEO Jayson Dallas Will Present at the Wedbush PacGrow Healthcare Conference on Wednesday, August 15th

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that Jayson Dallas, M.D., will give his first public presentation as the company’s President and CEO at the 2018 Wedbush PacGrow Healthcare Conference in New York on Wednesday, August 15 at 1:55 p.m. Eastern Ti...

Nestlé Increases Stake in Aimmune as Company Eyes Filing for FDA Approval of Peanut Allergy Medicine

As California-based Aimmune prepares to seek regulatory approval for its peanut allergy treatment, AR101, Nestlé Health Science has increased its financial stake in the food allergy prevention-focused company with another $98 million investment.

Aimmune Therapeutics Announces Data on Terminology Used with Oral Immunotherapy Were Presented ...

— U.S. Allergists Preferred “Tolerated Dose” as the Most Clinically Relevant Term to Communicate Desensitization Levels to Oral Immunotherapy Patients — Read more...

Aimmune Therapeutics Announces Presentations at 2018 ACAAI Annual Scientific Meeting

— Oral Presentation on Data from Aimmune’s Pivotal Phase 3 PALISADE Trial — — Additional Oral and E-Poster Presentations on AR101, Peanut Allergy and Oral Immunotherapy — Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced ...

Nestle ups stake in food allergy drug developer

Nestle’s health science arm will pay $98 million to raise its stake in Aimmune Therapeutics, as the drug developer prepares to submit a marketing application for its peanut allergy treatment before the end of the year.

Aimmune Therapeutics' Peanut Allergy Immunotherapy Looks Promising in Phase III Trial

It is estimated that 2.5 percent of all children in the U.S. might have a peanut allergy. Since 2010, according to the America College of Allergy, Asthma and Immunology, incidence of peanut allergies in children had risen 21 percent in the U.S.

Here, Take Another Hit Of This, Then Sell Some More Aimmune


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks